Poolman Jan T, Richmond Peter
Bacterial Vaccine Discovery & Early Development, Janssen, Zernikedreef 9; 2333 CK Leiden, The Netherlands.
Expert Rev Vaccines. 2015;14(9):1277-87. doi: 10.1586/14760584.2015.1071670. Epub 2015 Jul 23.
Vaccines targeting Neisseria meningitidis serogroup B (MenB) have been attempted for 40 years. Monovalent outer membrane vesicle vaccines targeted at epidemic outbreaks have been successfully developed. Newer vaccines aim to induce antibodies to cross-reactive antigens, such as factor H binding protein (rLP2086) or a mix of outer membrane vesicle, factor H binding protein and other minor antigens (4CMenB). The true protective coverage among circulating MenB isolates afforded by these vaccines is unknown. Carefully conducted Phase IV post-implementation evaluations designed to measure specific effectiveness against major circulating MenB clonal lineages are needed to address the critical question of which antigens are linked to protection. Progress with whole-genome sequencing and bio-informatics may allow the composition of antigen mozaics based on two major outer membrane proteins: PorA and FetA.
针对B群脑膜炎奈瑟菌（MenB）的疫苗研发已历经40年。针对疫情爆发的单价外膜囊泡疫苗已成功研制出来。新型疫苗旨在诱导产生针对交叉反应抗原的抗体，如H因子结合蛋白（rLP2086）或外膜囊泡、H因子结合蛋白及其他次要抗原的混合物（4CMenB）。这些疫苗对循环中的MenB分离株的实际保护覆盖率尚不清楚。需要精心开展实施后IV期评估，以衡量针对主要循环MenB克隆谱系的具体有效性，从而解决哪些抗原与保护作用相关这一关键问题。全基因组测序和生物信息学方面的进展可能会使基于两种主要外膜蛋白PorA和FetA的抗原组合成为可能。
